American Cancer Society recommends biennial PSA screening for average-risk men and annual testing for Black men
Միայն փաստեր

American Cancer Society recommends biennial PSA screening for average-risk men and annual testing for Black men

Ամփոփում

The ACS updated its prostate cancer screening guideline, advising men aged 50-69 at average risk to undergo PSA tests every two years and men aged 45-69 who are Black to be screened annually.

The American Cancer Society released its first revision to the prostate cancer screening guideline since 2010, shifting to a risk-based schedule. For men at average risk, the Society now advises a prostate-specific antigen (PSA) test every two years from age 50 through 69. Black men, as well as non-Black men with a first-degree relative diagnosed before age 65, are recommended to begin annual screening at age 45 and continue through age 69. Men with a single first-degree relative diagnosed at age 65 or older should follow the biennial schedule starting at age 45.

For ages 70-74, the guideline calls for individualized decision-making, while screening is not recommended for men 75 and older or for anyone with a life expectancy under ten years. Digital rectal examination is also excluded as a primary test. The recommendations do not apply to men with hereditary cancer syndromes such as BRCA2 mutations.

The update cites long-term trial data showing modest mortality benefits from PSA screening, including a 13% reduction in prostate cancer deaths in the European Randomized Study of Screening for Prostate Cancer and a 29% reduction in the Göteborg trial. Modeling by three Cancer Intervention and Surveillance Modeling Network teams projects that earlier, more frequent screening for Black men could save 28 to 36 lives per 1,000 screened, compared with 14 to 16 per 1,000 in the general population.

"By making a direct recommendation for men to engage in screening and advocating for earlier and more frequent screening for Black men, our aim is also to help reduce prostate cancer disparities and ease the disease burden," said William L. Dahut, MD, chief scientific officer of the ACS.

To limit overdiagnosis, the guideline sets the PSA threshold at 3.0 ng/mL for men under 70 and 6.5 ng/mL for those 70-74, with repeat testing before further evaluation. Elevated results should be followed by MRI or validated biomarker testing to guide biopsy decisions, and men diagnosed with low-risk disease are encouraged to pursue active surveillance. Modeling suggests that incorporating MRI could cut biopsies by up to a third and reduce overdiagnoses while modestly increasing lives saved.

Աղբյուր

CancerNetwork

Շարունակեք կարդալ — անվճար

Ստեղծեք անվճար հաշիվ՝ նորություններին հետևելու համար։ Քարտ չի պահանջվում։